Praxis Precision Medicines Inc. (Praxis Precision Medicines (PRAX)) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures, and the news was a bit of a mixed bag. The overall outcome didn't hit the mark, but there were some encouraging signs for the higher-dose group.

The study, which focused on patients with highly refractory focal onset seizures (seizures that start in a specific area of the brain), failed to meet its primary endpoint: a statistically significant reduction in monthly seizure frequency. That's the headline number, and it's not what anyone wanted to see.

But dig a little deeper, and there's a more nuanced story. The secondary measure—the 50% response rate—was actually met. And when you look at the higher dose of 30 mg, the seizure reduction during the second half of the study was more pronounced. That's the kind of signal that keeps drug developers hopeful.

"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate, and solid safety profile," said Souza, the company's CEO, in a statement.

One of the most telling numbers might be this: 90% of patients from the vormatrigine arm chose to transition into the open-label extension (OLE) study, and they've stayed there. That suggests patients are tolerating the drug well and, presumably, getting some benefit—otherwise, why stick around?

Praxis is now pausing enrollment in the POWER2 study to take a step back and reassess the vormatrigine program. The goal is to figure out potential modifications—maybe tweaking the dosing or the patient population—to improve the chances of success in future trials.

Meanwhile, the company isn't putting all its eggs in one basket. Praxis is also focused on preparing for the planned launches of relutrigine and ulixacaltamide, two other pipeline candidates. So there's still plenty to keep investors busy.

Looking back at the preclinical data, vormatrigine had shown some interesting properties. Laboratory studies suggested it might be selective for disease-state sodium channel hyperexcitability—basically, it targets the overactive channels in epileptic brains without messing with normal ones. Animal studies also showed strong activity in the maximal electroshock seizure model, a standard test for predicting efficacy in focal epilepsy. And earlier data from the RADIANT study had shown seizure reduction and a generally safe profile.

In April, Praxis also released positive results from the EMBRAVE Part A trial of elsunersen for SCN2A early-onset developmental and epileptic encephalopathy. That drug showed a placebo-adjusted seizure reduction of 77% from baseline in pediatric patients—a pretty impressive number.

Investors, however, are focused on the here and now. Shares of Praxis were down 9.30% in premarket trading on Tuesday, trading at $304.00. That's a meaningful drop, but not a total collapse—the market seems to be weighing the disappointment against the glimmers of hope.

For a biotech company, this is the kind of news that tests your narrative. The POWER1 study didn't deliver a clean win, but it also didn't blow up. The higher-dose signal, the strong OLE enrollment, and the safety profile all give Praxis something to work with. The question now is whether they can turn that signal into a statistically significant result in future trials.